Selected research
Industry Research
Endocrine Therapy Drugs (ETDs) Industry Research Report 2026
Market perspective
The global Endocrine Therapy Drugs (ETDs) market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Endocrine Therapy Drugs (ETDs) is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Endocrine Therapy Drugs (ETDs) is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Endocrine Therapy Drugs (ETDs) is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Endocrine Therapy Drugs (ETDs) include Sanofi, Pfizer, Bayer, AstraZeneca, Tonghua Dongbao Pharmaceutical, Novo Nordisk, MSD, Huadong Medicine and Generex Biotechnology, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Endocrine Therapy Drugs (ETDs) market in terms of revenue (US$ million) and, where applicable, sales volume (Tons), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/Tons) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Endocrine Therapy Drugs (ETDs) Market by Company
Sanofi
Pfizer
Bayer
AstraZeneca
Tonghua Dongbao Pharmaceutical
Novo Nordisk
MSD
Huadong Medicine
Generex Biotechnology
Endocrine Therapy Drugs (ETDs) Segment by Type
Antidiabetic Drugs
Anti-osteoporosis Drugs
Contraceptive
Other
Endocrine Therapy Drugs (ETDs) Segment by Application
Diabetes Treatment
Osteoporosis Treatment
Contraception
Other
Endocrine Therapy Drugs (ETDs) Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Endocrine Therapy Drugs (ETDs) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Endocrine Therapy Drugs (ETDs) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Endocrine Therapy Drugs (ETDs).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Endocrine Therapy Drugs (ETDs) manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Endocrine Therapy Drugs (ETDs) by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Endocrine Therapy Drugs (ETDs) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Antidiabetic Drugs
- Anti-osteoporosis Drugs
- Contraceptive
- Other
Applications
- Diabetes Treatment
- Osteoporosis Treatment
- Contraception
- Other
Companies covered
- Sanofi
- Pfizer
- Bayer
- AstraZeneca
- Tonghua Dongbao Pharmaceutical
- Novo Nordisk
- MSD
- Huadong Medicine
- Generex Biotechnology
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Endocrine Therapy Drugs (ETDs) Market Size (2021-2032)
- 2.2.2 Global Endocrine Therapy Drugs (ETDs) Sales (2021-2032)
- 2.2.3 Global Endocrine Therapy Drugs (ETDs) Market Average Price (2021-2032)
- 2.3 Endocrine Therapy Drugs (ETDs) by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Antidiabetic Drugs
- 2.3.3 Anti-osteoporosis Drugs
- 2.3.4 Contraceptive
- 2.3.5 Other
- 2.4 Endocrine Therapy Drugs (ETDs) by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Diabetes Treatment
- 2.4.3 Osteoporosis Treatment
- 2.4.4 Contraception
- 2.4.5 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Endocrine Therapy Drugs (ETDs) Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Endocrine Therapy Drugs (ETDs) Sales (Tons) of Manufacturers (2021-2026)
- 3.3 Global Endocrine Therapy Drugs (ETDs) Revenue of Manufacturers (2021-2026)
- 3.4 Global Endocrine Therapy Drugs (ETDs) Average Price by Manufacturers (2021-2026)
- 3.5 Global Endocrine Therapy Drugs (ETDs) Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Endocrine Therapy Drugs (ETDs), Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Endocrine Therapy Drugs (ETDs), Product Type & Application
- 3.8 Global Manufacturers of Endocrine Therapy Drugs (ETDs), Established Date
- 3.9 Global Endocrine Therapy Drugs (ETDs) Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Sanofi
- 4.1.1 Sanofi Company Information
- 4.1.2 Sanofi Business Overview
- 4.1.3 Sanofi Endocrine Therapy Drugs (ETDs) Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Sanofi Endocrine Therapy Drugs (ETDs) Product Portfolio
- 4.1.5 Sanofi Recent Developments
- 4.2 Pfizer
- 4.2.1 Pfizer Company Information
- 4.2.2 Pfizer Business Overview
- 4.2.3 Pfizer Endocrine Therapy Drugs (ETDs) Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Pfizer Endocrine Therapy Drugs (ETDs) Product Portfolio
- 4.2.5 Pfizer Recent Developments
- 4.3 Bayer
- 4.3.1 Bayer Company Information
- 4.3.2 Bayer Business Overview
- 4.3.3 Bayer Endocrine Therapy Drugs (ETDs) Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Bayer Endocrine Therapy Drugs (ETDs) Product Portfolio
- 4.3.5 Bayer Recent Developments
- 4.4 AstraZeneca
- 4.4.1 AstraZeneca Company Information
- 4.4.2 AstraZeneca Business Overview
- 4.4.3 AstraZeneca Endocrine Therapy Drugs (ETDs) Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 AstraZeneca Endocrine Therapy Drugs (ETDs) Product Portfolio
- 4.4.5 AstraZeneca Recent Developments
- 4.5 Tonghua Dongbao Pharmaceutical
- 4.5.1 Tonghua Dongbao Pharmaceutical Company Information
- 4.5.2 Tonghua Dongbao Pharmaceutical Business Overview
- 4.5.3 Tonghua Dongbao Pharmaceutical Endocrine Therapy Drugs (ETDs) Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Tonghua Dongbao Pharmaceutical Endocrine Therapy Drugs (ETDs) Product Portfolio
- 4.5.5 Tonghua Dongbao Pharmaceutical Recent Developments
- 4.6 Novo Nordisk
- 4.6.1 Novo Nordisk Company Information
- 4.6.2 Novo Nordisk Business Overview
- 4.6.3 Novo Nordisk Endocrine Therapy Drugs (ETDs) Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Novo Nordisk Endocrine Therapy Drugs (ETDs) Product Portfolio
- 4.6.5 Novo Nordisk Recent Developments
- 4.7 MSD
- 4.7.1 MSD Company Information
- 4.7.2 MSD Business Overview
- 4.7.3 MSD Endocrine Therapy Drugs (ETDs) Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 MSD Endocrine Therapy Drugs (ETDs) Product Portfolio
- 4.7.5 MSD Recent Developments
- 4.8 Huadong Medicine
- 4.8.1 Huadong Medicine Company Information
- 4.8.2 Huadong Medicine Business Overview
- 4.8.3 Huadong Medicine Endocrine Therapy Drugs (ETDs) Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Huadong Medicine Endocrine Therapy Drugs (ETDs) Product Portfolio
- 4.8.5 Huadong Medicine Recent Developments
- 4.9 Generex Biotechnology
- 4.9.1 Generex Biotechnology Company Information
- 4.9.2 Generex Biotechnology Business Overview
- 4.9.3 Generex Biotechnology Endocrine Therapy Drugs (ETDs) Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Generex Biotechnology Endocrine Therapy Drugs (ETDs) Product Portfolio
- 4.9.5 Generex Biotechnology Recent Developments
5 Global Endocrine Therapy Drugs (ETDs) Market Scenario by Region
- 5.1 Global Endocrine Therapy Drugs (ETDs) Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Endocrine Therapy Drugs (ETDs) Sales by Region: 2021-2032
- 5.2.1 Global Endocrine Therapy Drugs (ETDs) Sales by Region: 2021-2026
- 5.2.2 Global Endocrine Therapy Drugs (ETDs) Sales by Region: 2027-2032
- 5.3 Global Endocrine Therapy Drugs (ETDs) Revenue by Region: 2021-2032
- 5.3.1 Global Endocrine Therapy Drugs (ETDs) Revenue by Region: 2021-2026
- 5.3.2 Global Endocrine Therapy Drugs (ETDs) Revenue by Region: 2027-2032
- 5.4 North America Endocrine Therapy Drugs (ETDs) Market Facts & Figures by Country
- 5.4.1 North America Endocrine Therapy Drugs (ETDs) Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Endocrine Therapy Drugs (ETDs) Sales by Country (2021-2032)
- 5.4.3 North America Endocrine Therapy Drugs (ETDs) Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Endocrine Therapy Drugs (ETDs) Market Facts & Figures by Country
- 5.5.1 Europe Endocrine Therapy Drugs (ETDs) Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Endocrine Therapy Drugs (ETDs) Sales by Country (2021-2032)
- 5.5.3 Europe Endocrine Therapy Drugs (ETDs) Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Endocrine Therapy Drugs (ETDs) Market Facts & Figures by Country
- 5.6.1 Asia Pacific Endocrine Therapy Drugs (ETDs) Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Endocrine Therapy Drugs (ETDs) Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Endocrine Therapy Drugs (ETDs) Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Endocrine Therapy Drugs (ETDs) Market Facts & Figures by Country
- 5.7.1 South America Endocrine Therapy Drugs (ETDs) Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Endocrine Therapy Drugs (ETDs) Sales by Country (2021-2032)
- 5.7.3 South America Endocrine Therapy Drugs (ETDs) Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Endocrine Therapy Drugs (ETDs) Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Endocrine Therapy Drugs (ETDs) Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Endocrine Therapy Drugs (ETDs) Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Endocrine Therapy Drugs (ETDs) Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Endocrine Therapy Drugs (ETDs) Sales by Type (2021-2032)
- 6.1.1 Global Endocrine Therapy Drugs (ETDs) Sales by Type (2021-2032) & (Tons)
- 6.1.2 Global Endocrine Therapy Drugs (ETDs) Sales Market Share by Type (2021-2032)
- 6.2 Global Endocrine Therapy Drugs (ETDs) Revenue by Type (2021-2032)
- 6.2.1 Global Endocrine Therapy Drugs (ETDs) Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Endocrine Therapy Drugs (ETDs) Revenue Market Share by Type (2021-2032)
- 6.3 Global Endocrine Therapy Drugs (ETDs) Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Endocrine Therapy Drugs (ETDs) Sales by Application (2021-2032)
- 7.1.1 Global Endocrine Therapy Drugs (ETDs) Sales by Application (2021-2032) & (Tons)
- 7.1.2 Global Endocrine Therapy Drugs (ETDs) Sales Market Share by Application (2021-2032)
- 7.2 Global Endocrine Therapy Drugs (ETDs) Revenue by Application (2021-2032)
- 7.2.1 Global Endocrine Therapy Drugs (ETDs) Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Endocrine Therapy Drugs (ETDs) Revenue Market Share by Application (2021-2032)
- 7.3 Global Endocrine Therapy Drugs (ETDs) Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Endocrine Therapy Drugs (ETDs) Value Chain Analysis
- 8.1.1 Endocrine Therapy Drugs (ETDs) Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Endocrine Therapy Drugs (ETDs) Production Mode & Process
- 8.2 Endocrine Therapy Drugs (ETDs) Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Endocrine Therapy Drugs (ETDs) Distributors
- 8.2.3 Endocrine Therapy Drugs (ETDs) Customers
9 Global Endocrine Therapy Drugs (ETDs) Analyzing Market Dynamics
- 9.1 Endocrine Therapy Drugs (ETDs) Industry Trends
- 9.2 Endocrine Therapy Drugs (ETDs) Industry Drivers
- 9.3 Endocrine Therapy Drugs (ETDs) Industry Opportunities and Challenges
- 9.4 Endocrine Therapy Drugs (ETDs) Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst